Kymera Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Oct 29, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Oct 29, 2026

KYMR$136.64-1.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

STOCKHOLDERS’ EQUITY

For the three months ended September 30, 2026 and 2025

(In thousands, except for share amounts)

Common Stock · AdditionalPaid in · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’
	Shares	Value	Capital	Deficit	Gain (Loss)	Equity
Balance at June 30, 2025	70,557,442	$7	$1,867,999	$(896,805)	$279	971,480
Issuance of common stock from June 2025 public offering, net of issuance costs of $2.2 million	855,000	—	35,376	—	—	35,376
Exercise of stock options	275,484	—	4,553	—	—	4,553
Vesting restricted stock	53,248	—	—	—	—	—
Issuance of shares under employee stock purchase plan	—	—	—	—	—	—
Stock-based compensation expense	—	—	15,802	—	—	15,802
Unrealized gain on marketable securities	—	—	—	—	1,222	1,222
Net loss	—	—	—	(82,175)	—	(82,175)
Balance at September 30, 2025	71,741,174	$7	$1,923,730	$(978,980)	$1,501	$946,258
Balance at June 30, 2026	82,788,253	$8	$2,712,811	$(1,196,406)	$(7,157)	$1,509,256
Issuance of common stock through at-the-market sales agreement, net of issuance costs of $4.5 million	2,032,140	1	215,392	—	—	215,393
Exercise of stock options	375,564	—	10,618	—	—	10,618
Vesting restricted stock	129,546	—	—	—	—	—
Stock-based compensation expense	—	—	18,837	—	—	18,837
Unrealized loss on marketable securities	—	—	-	—	(7,578)	(7,578)
Net loss	—	—	-	(131,999)	—	(131,999)
Balance at September 30, 2026	85,325,503	$9	$2,957,658	$(1,328,405)	$(14,735)	$1,614,527

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

For the nine months ended September 30, 2026 and 2025

(In thousands, except for share amounts)

Common Stock · AdditionalPaid in · Accumulated · AccumulatedOtherComprehensive · TotalStockholders'
	Shares	Value	Capital	Deficit	Gain (Loss)	Equity
Balance at December 31, 2024	64,890,193	$7	$1,591,707	$(754,610)	$(1,485)	$835,619
Issuance of common stock and accompanying pre-funded warrants from June 2025 public offering, net of issuance costs of $15.7 million	5,899,500	—	272,671	—	—	272,671
Exercise of stock options	629,222	—	12,789	—	—	12,789
Vesting restricted stock	278,130	—	—	—	—	—
Issuance of shares under employee stock purchase plan	44,129	—	1,112	—	—	1,112
Stock-based compensation expense	—	—	45,451	—	—	45,451
Unrealized gain on marketable securities	—	—	—	—	2,986	2,986
Net loss	—	—	—	(224,370)	—	(224,370)
Balance at September 30, 2025	71,741,174	$7	$1,923,730	$(978,980)	$1,501	$946,258
Balance at December 31, 2025	81,323,532	$8	$2,643,817	$(1,065,961)	$1,800	$1,579,664
Issuance of common stock through at-the-market sales agreement, net of issuance costs of $4.5 million	2,032,140	1	215,392	—	—	215,393
Exercise of stock options	1,563,730	—	43,195	—	—	43,195
Vesting restricted stock	380,149	—	—	—	—	—
Issuance of shares under employee stock purchase plan	25,952	—	1,472	—	—	1,472
Stock-based compensation expense	—	—	53,782	—	—	53,782
Unrealized loss on marketable securities	—	—	—	—	(16,535)	(16,535)
Net loss	—	—	—	(262,444)	—	(262,444)
Balance at September 30, 2026	85,325,503	9	2,957,658	(1,328,405)	(14,735)	1,614,527

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.